Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Placebo? no thanks, it might be bad for me!
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.
Solodyn
Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.
Using experimental autoimmune encephalomyelitis as a model to study the effect of prenatal stress on fetal programming.
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Ocrelizumab in multiple sclerosis: risks and benefits.
High risk of MS in Iranian immigrants in Gothenburg, Sweden.
Noninvasive molecular imaging of neuroinflammation.
Protective Associations of HDL with Blood Brain Barrier Injury in Multiple Sclerosis Patients.
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis.
An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
The VP1 subunit of JC polyomavirus recapitulates early events in viral trafficking and is a novel tool to study polyomavirus entry.
Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, th17- and activated B-cells and correlates with progression.
Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
The mammalian Na+/H+ exchanger gene family--initial structure/function studies.
The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.
How Natalizumab Binds and Antagonizes α4 Integrins.
Birth outcomes of pregnancies fathered by men with multiple sclerosis.
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.
Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica.
Quantitative assessment of multiple sclerosis using inertial sensors and the TUG test.
Psoriasis during natalizumab treatment for multiple sclerosis.
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.

Pages